Oncopeptides Withdraws Pepaxto? in US, Scale Down Organization and Focus on R&D
Oncopeptides AB announced that the company has decided to withdraw Pepaxto? from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with... | October 23, 2021
European Medicines Agency Drug Administration Peptide Drug Conjugate Conditional Marketing Authorization Oncopeptides Ab Publ Stock Exchange Press Release
Source: marketscreener.com